ArticleScientific reports2023
Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hemodynamic Alterations in Liver Cirrhosis Compared to Healthy Subjects: Assessment of Non-invasive MRI and Echocardiography Compared to Liver Vein Catheterization
Copenhagen Liver Cohort Study: Disease Characteristics, Outcomes and Rehabilitation in Liver Cirrhosis - A Prospective Cohort Study
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Wearable Sweat Biosensors for Inflammatory Biomarkers (CRP, IL-6 and TNF-α): A Systematic Review of Analytical and Clinical Evidence.Biosensors · 2026Pooled it
- Renal Impairment as an Independent Predictor of Sepsis in Cirrhosis: A Retrospective Cohort Study.Microorganisms · 2026Article
- The predictive role of ammonia in liver-related decompensation and mortality in patients with compensated cirrhosis: A retrospective cohort study.Canadian liver journal · 2026Article
- Observational
- A cluster analysis of 466 patients demonstrates that glutathione supplementation could preferentially benefit advanced unstable cirrhosis phenotype rather than stable cirrhosis.Frontiers in pharmacology · 2026Article
- Particularly strong immune response to influenza vaccination in patients with decompensated liver cirrhosis linked to systemic inflammation.Frontiers in immunology · 2026Observational
- Beyond traditional-the sick cirrhosis patient scores integrating cytokine and immune profiling for precision prognosis in hospitalized cirrhosis patients may help predict infection, ICU admission and long-term death post hospitalization.Frontiers in medicine · 2026Article
- Risk factors, clinical outcomes, and the development of a pragmatic zinc deficiency screening tool in patients with cirrhosis: a prospective cohort study.European journal of clinical nutrition · 2026Article
- Hepatic Inflammation and Liver Injury in a Model of Bacterial Infection Triggered Acute-on-Chronic Liver Injury.Journal of gastroenterology and hepatology · 2025Article
- Identifying a unique signature of sepsis in patients with pre-existing cirrhosis.Critical care (London, England) · 2025Article
- Beyond Liver Function:Sultan Qaboos University medical journal · 2025Article
- Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis.Cureus · 2025Review
- Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) and mortality among survivors of liver cirrhosis: a prospective cohort study.Nutrition journal · 2025Article
- Artificial intelligence-based evaluation of prognosis in cirrhosis.Journal of translational medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
The inflammatory activity in cirrhosis is often pronounced and related to episodes of decompensation. Systemic markers of inflammation may contain prognostic information, and we investigated their possible correlation with admissions and mortality among patients with newly diagnosed liver cirrhosis. We collected plasma samples from 149 patients with newly diagnosed (within the past 6 months) cirrhosis, and registered deaths and hospital admissions within 180 days. Ninety-two inflammatory markers were quantified and correlated with clinical variables, mortality, and admissions. Prediction models were calculated by logistic regression. We compared the disease courses of our cohort with a validation cohort of 86 patients with cirrhosis. Twenty of 92 markers of inflammation correlated significantly with mortality within 180 days (q-values of 0.00-0.044), whereas we found no significant correlations with liver-related admissions. The logistic regression models yielded AUROCs of 0.73 to 0.79 for mortality and 0.61 to 0.73 for liver-related admissions, based on a variety of modalities (clinical variables, inflammatory markers, clinical scores, or combinations thereof). The models performed moderately well in the validation cohort and were better able to predict mortality than liver-related admissions. In conclusion, markers of inflammation can be used to predict 180-day mortality in patients with newly diagnosed cirrhosis. Prediction models for newly diagnosed cirrhotic patients need further validation before implementation in clinical practice.Trial registration: NCT04422223 (and NCT03443934 for the validation cohort), and Scientific Ethics Committee No.: H-19024348.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.